Jenburkt Pharmaceuticals Ltd Financials

Jenburkt Pharmaceuticals Ltd Financial Statement

Jenburkt Pharmaceuticals Ltd Income Statement

Quarterly

Annual

*All values are in Rs. Cr

Particulars	Sep 2024	Jun 2024	Mar 2024
Revenue	43.07	33.94	40.03
Operating Expense	29.79	23.25	28.99
Net Profit	9.60	7.42	7.88
Net Profit Margin	22.29	21.86	19.69
Earning Per Share	21.75	16.80	17.86
EBIDTA	13.36	10.55	11.21
Effective Tax Rate	22.59	23.36	24.00

Particulars	Sep 2024
Revenue	43.07
Operating Expense	29.79
Net Profit	9.60
Net Profit Margin	22.29
Earning Per Share	21.75
EBIDTA	13.36
Effective Tax Rate	22.59

Jenburkt Pharmaceuticals Ltd Profit & Loss

*All values are in Rs. Cr

Standalone

Consolidated

Particulars	Mar 2024	Mar 2023	Mar 2022
Total Revenue Annual	141.97	136.75	123.98
Operating Expenses Annual	108.85	106.38	96.73
Operating Profit Annual	37.79	35.49	32.20
Interest Annual	0.27	0.37	0.43
Depreciation	2.34	2.26	1.90
Net Profit Annual	25.98	24.61	22.30
Tax Annual	9.20	8.26	7.57

Particulars	Mar 2024
Total Revenue Annual	141.97
Operating Expenses Annual	108.85
Operating Profit Annual	37.79
Interest Annual	0.27
Depreciation	2.34
Net Profit Annual	25.98
Tax Annual	9.20

Jenburkt Pharmaceuticals Ltd Cash Flow

*All values are in Rs. Cr

Standalone

Consolidated

Particulars	Mar 2024	Mar 2023	Mar 2022
Cash Flow at the Beginning	3.66	5.03	2.49
Cash Flow from Operations	8.12	17.05	9.27
Cash Flow from Investing	-0.58	2.62	-1.20
Cash Flow from Financing	-7.08	-21.04	-5.53
Cash Flow at the End	4.13	3.66	5.03

Particulars	Mar 2024
Cash Flow at the Beginning	3.66
Cash Flow from Operations	8.12
Cash Flow from Investing	-0.58
Cash Flow from Financing	-7.08
Cash Flow at the End	4.13

Jenburkt Pharmaceuticals Ltd Key Ratios

*All values are in Rs. Cr

Standalone

Consolidated

Particulars	Mar 2024	Mar 2023	Mar 2022
PBDIT Margin (%)	26.62	25.95	25.97
PBIT Margin (%)	24.97	24.30	24.44
PBT Margin (%)	-67.51	-41.40	-32.40
Net PROFIT Margin (%)	18.30	18.00	17.99
Return On Networth / Equity (%)	19.44	20.53	20.66
Return On Networth /Employed (%)	25.67	26.04	25.94
Return On Assets (%)	18.85	19.26	19.07
Total Debt / Equity (X)	0.01	0.04	0.05
Asset Turnover Ratio (%)	1.03	1.07	1.06

Particulars	Mar 2024
PBDIT Margin (%)	26.62
PBIT Margin (%)	24.97
PBT Margin (%)	-67.51
Net PROFIT Margin (%)	18.30
Return On Networth / Equity (%)	19.44
Return On Networth /Employed (%)	25.67
Return On Assets (%)	18.85
Total Debt / Equity (X)	0.01
Asset Turnover Ratio (%)	1.03

Jenburkt Pharmaceuticals Ltd Balance Sheet

*All values are in Rs. Cr

Standalone

Consolidated

Particulars	Mar 2024	Mar 2023	Mar 2022
Fixed Assets Annual	10.36	10.45	11.40
Total Current Assets Annual	109.73	81.09	75.90
Non Current Assets Annual	55.37	60.72	67.05
Total Shareholders Funds Annual	144.94	122.39	117.38
Total Assets Annual	165.10	141.81	142.95

Particulars	Mar 2024
Fixed Assets Annual	10.36
Total Current Assets Annual	109.73
Non Current Assets Annual	55.37
Total Shareholders Funds Annual	144.94
Total Assets Annual	165.10

Jenburkt Pharmaceuticals Ltd Earning Calls

No Data Availabe

Dividend Pages

PE Ratio

Get Your FAQs Right

As of Dec 26, 2024, Jenburkt Pharmaceuticals Ltd has a market capitalization of 304.27 Cr. Value Research classifies it as a Small-Cap company.

Yes, Jenburkt Pharmaceuticals Ltd is debt-free with a debt-to-equity ratio of 0.00.

In FY 2023 , Jenburkt Pharmaceuticals Ltd recorded a total revenue of approximately 141.97 Cr marking a significant milestone in the company's financial performance.

Jenburkt Pharmaceuticals Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately 0.1% and 0.1% annually, respectively..

Jenburkt Pharmaceuticals Ltd's current PE ratio is 11.71.

Jenburkt Pharmaceuticals Ltd's ROCE averaged 24.6% from the FY ending March 2022 to 2024, with a median of 24.0%. It peaked at 25.9% in March 2023, reflecting strong capital efficiency over the period..

Jenburkt Pharmaceuticals Ltd's latest EBIT is Rs. 35.45 Cr, surpassing the average EBIT of Rs. 32.99 Cr over the 5 years..